Show simple item record

dc.contributor.authorJames, Nicholas D
dc.contributor.authorIngleby, Fiona C
dc.contributor.authorClarke, Noel W
dc.contributor.authorAmos, Claire L
dc.contributor.authorAttard, Gerhardt
dc.contributor.authorBrawley, Christopher D
dc.contributor.authorChowdhury, Simon
dc.contributor.authorCross, William
dc.contributor.authorDearnaley, David P
dc.contributor.authorGilbert, Duncan C
dc.contributor.authorGillessen, Silke
dc.contributor.authorJones, Robert J
dc.contributor.authorLangley, Ruth E
dc.contributor.authorMacnair, Archie
dc.contributor.authorMalik, Zafar I
dc.contributor.authorMason, Malcolm D
dc.contributor.authorMatheson, David
dc.contributor.authorMillman, Robin
dc.contributor.authorParker, Chris C
dc.contributor.authorRush, Hannah L
dc.contributor.authorRussell, J Martin
dc.contributor.authorAu, Carly
dc.contributor.authorRitchie, Alastair WS
dc.contributor.authorMestre, Ricardo Pereira
dc.contributor.authorAhmed, Imtiaz
dc.contributor.authorBirtle, Alison J
dc.contributor.authorBrock, Susannah J
dc.contributor.authorDas, Prantik
dc.contributor.authorFord, Victoria A
dc.contributor.authorGray, Emma K
dc.contributor.authorHughes, Robert J
dc.contributor.authorManetta, Caroline B
dc.contributor.authorMcLaren, Duncan B
dc.contributor.authorNikapota, Ashok D
dc.contributor.authorO’Sullivan, Joe M
dc.contributor.authorPerna, Carla
dc.contributor.authorPeedell, Clive
dc.contributor.authorProtheroe, Andrew S
dc.contributor.authorSundar, Santhanam
dc.contributor.authorTanguay, Jacob S
dc.contributor.authorTolan, Shaun P
dc.contributor.authorWagstaff, John
dc.contributor.authorWallace, Jan B
dc.contributor.authorWylie, James P
dc.contributor.authorZarkar, Anjali
dc.contributor.authorParmar, Mahesh KB
dc.contributor.authorSydes, Matthew R
dc.identifier.citationJames, N.D., Ingleby, F.C., Clarke, N.W. et al. (2022) Docetaxel for nonmetastatic prostate cancer: Long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI Cancer Spectrum, 6(4), pkac043.en
dc.description© 2022 The Authors. Published by OUP. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website:
dc.description.abstractBackground STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy. We report long-term results for non-metastatic patients using, as primary outcome, metastatic progression-free survival (mPFS), an externally demonstrated surrogate for overall survival. Methods Standard of care (SOC) was androgen deprivation therapy with or without radical prostate radiotherapy. A total of 460 SOC and 230 SOC plus docetaxel were randomly assigned 2:1. Standard survival methods and intention to treat were used. Treatment effect estimates were summarized from adjusted Cox regression models, switching to restricted mean survival time if non-proportional hazards. mPFS (new metastases, skeletal-related events, or prostate cancer death) had 70% power (α = 0.05) for a hazard ratio (HR) of 0.70. Secondary outcome measures included overall survival, failure-free survival (FFS), and progression-free survival (PFS: mPFS, locoregional progression). Results Median follow-up was 6.5 years with 142 mPFS events on SOC (3 year and 54% increases over previous report). There was no good evidence of an advantage to SOC plus docetaxel on mPFS (HR = 0.89, 95% confidence interval [CI] = 0.66 to 1.19; P = .43); with 5-year mPFS 82% (95% CI = 78% to 87%) SOC plus docetaxel vs 77% (95% CI = 73% to 81%) SOC. Secondary outcomes showed evidence SOC plus docetaxel improved FFS (HR = 0.70, 95% CI = 0.55 to 0.88; P = .002) and PFS (nonproportional P = .03, restricted mean survival time difference = 5.8 months, 95% CI = 0.5 to 11.2; P = .03) but no good evidence of overall survival benefit (125 SOC deaths; HR = 0.88, 95% CI = 0.64 to 1.21; P = .44). There was no evidence SOC plus docetaxel increased late toxicity: post 1 year, 29% SOC and 30% SOC plus docetaxel grade 3-5 toxicity. Conclusions There is robust evidence that SOC plus docetaxel improved FFS and PFS (previously shown to increase quality-adjusted life-years), without excess late toxicity, which did not translate into benefit for longer-term outcomes. This may influence patient management in individual cases.en
dc.description.sponsorshipThis work was supported by Cancer Research UK (grant number CRUK_A12459); Medical Research Council (grant number MRC_MC_UU_12023/25, grant number MC_UU_00004/01); Sanofi; Astellas; Clovis; Janssen; Novartis; Pfizer. NDJ, CCP, and DPD were supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London.en
dc.publisherOxford University Pressen
dc.subjectnon-metastatic prostate canceren
dc.subjectrandomized controlled trialen
dc.titleDocetaxel for nonmetastatic prostate cancer: Long-term survival outcomes in the STAMPEDE randomized controlled trialen
dc.typeJournal articleen
dc.identifier.journalJNCI Cancer Spectrumen
rioxxterms.funderCancer Research UK, Medical Research Council, Sanofi, Astellas, Clovis, Janssen, Novartis, Pfizer, National Institute for Health Research Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Londonen
rioxxterms.identifier.projectCRUK_A12459, MRC_MC_UU_12023/25, MC_UU_00004/01en
dc.description.versionPublished version

Files in this item

JNCI July 22.pdf

This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as